TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Quantification of endogenous metabolites (urine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment Response of CABP Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days to return to activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Length of canalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reversal of serum iron debt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of patients alive without neurological sequelae
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of patients alive
Endpoint domain: Mortality/survival
Primary endpoint: Total Protein and Total Lysosome Deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of Cytokines and Albumin in Tear Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-RNA decay kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Glycaemic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects With a Vaccine Response for Serum Bactericidal Assay Using Rabbit Complement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With a Vaccine Response for Serum Bactericidal Assay Using Human Complement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reach of LIVE
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to LIVE
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Drop out from LIVE
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in numbers of CTCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who lose at least 5% of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Days Spent on Mechanical Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients who are candidates for ovarian tissue autograft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of grade ≥ 3 radiation dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Preoperative microorganism colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequency of deviant sexual activity per month
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Bone Mineral Density of Bone Core
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Volume Fraction of Bone Core
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standing Coronal Spinal Xrays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent reduction in iDSA and/or iAb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Superior Vena Cava Flow (SVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient Perception of Treatment Benefit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Willingness to Continue Treatment
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Rate of change in lung function (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall functionality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Brain glutamate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Implant Fixation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety and Performance
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who have had a conversation with a health care provider about ACP or GCD
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in health care costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in total volumetric bone mineral density of the distal femur
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: EPIC Urinary Incontinence subscale score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Positive Margin Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Composite Responders at Month 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relative fecal wet weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to Complete Eschar Removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in cellular properties of mesenchymal stromal cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucus concentration (% solids)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of Risky Drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Treated With Anticoagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Roll Evaluation of Activities of Life (REAL) assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bladder volume differential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Correctness of the shoulder movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total area of delayed enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Congruity between palpatory technique and ultrasound evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean headache days per month
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in C-Reactive Protein (CRP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy/ Clinical Global Impression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Personal and Social Performance Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Extrapyramidal Symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Participant ratings of negative (vasovagal) reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Phlebotomist ratings of donor reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of repeat donations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mealtime behaviours
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: American College of Rheumatology 50 response rate (ACR50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and nature of dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic image quality assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual assessment of contrast enhancement and vascular structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sputum Eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence or absence of olfactory disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of taste disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of good responders to combined treatment regarding body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour blood pressure control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of osteoblastic cells obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose Limiting Toxicity of PY314
Endpoint domain: Adverse events/effects
Primary endpoint: Stage of chronic kidney disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Inhibitor recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lens Wettability - ex-vivo wetting angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CA19-9 Plasma Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tenofovir Systemic Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Emtricitabine Systemic Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Atazanavir Systemic Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ritonavir Systemic Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: endotoxin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in serum AMH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Success in recruiting and establishing a pilot cohort
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Objective Response in solid tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive skills assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: NRS (numerical rating scale) for pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in PDQ39 summary index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Provocative Concentration of Methacholine (PC20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total number of days spent in hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Inflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-inflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Success on the Evaluator's Global Severity Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postoperative time to return to active bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from Baseline pain on walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latch Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing a Treatment Emergent Adverse Event After Single Administration of AGN-241622
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Experiencing a Treatment Emergent Adverse Event After Repeat Administration of AGN-241622
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative minimal hepatic encephalopathy (MHE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sustained virologic response at 12 weeks after end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of histologically confirmed CIN2 or worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection rate ratio of CIN2+ in HPV test vs cytology arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sebum secretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Communication with Parent
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prosthesis failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Distance Bright Illumination Binocular Visual Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near Bright Illumination Binocular Visual Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Subjective Vision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients preferring each treatment regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Performance agreement of ACR |LAB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Agreement of HTLV Blot 2.4 results with Reference Core Laboratory HTLV Algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of HTLV Blot 2.4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waist-Hip Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: birth outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: neonatal complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Fat free Cross Sectional Area (CSA) of upper leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Identification of a pulmonary nodule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of gene expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombelastography (TEG) results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or discharge
Endpoint domain: Mortality/survival
Primary endpoint: Sub-score in part A of the QECIEM questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Subjects with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Subjects with serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Time from study drug administration to discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Adherence to methotrexate (MTX)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of AR-67 in treating MDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of SCD related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak venous velocity (PVV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time averaged mean velocity (TAMV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average duration of blood pulse (ADBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ejection volume (EV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inflammation markers in blood plasma (IL-6, TNF-alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to long term care placement or death
Endpoint domain: Mortality/survival
Primary endpoint: Mean maximum observed concentration (Cmax) of E6742
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time at which the highest drug concentration occurs (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum-tolerated-dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACE activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delta (Δ) Sequential Organ Failure Assessment (SOFA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of OAA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid intima-media thickness change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in RLS symptom severity using IRLS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects responding to treatment using CGI-I scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants with perioperative infection
Endpoint domain: Adverse events/effects
Primary endpoint: Neurological impact
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acquired cardiovascular disease risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the Insulin Degludec concentration-time curve from 0 to 120 hours after single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum observed Insulin Degludec concentration after single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Identification of specific forms of circulating microRNAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of acne-like skin rash grade ≥ 2
Endpoint domain: Adverse events/effects
Primary endpoint: Blood circulating endotoxin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distant recurrence-free interval (D-RFI) rate
Endpoint domain: Mortality/survival
Primary endpoint: Mean number of catheter related blood stream infections (CRBSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Geriatric Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative morbidity score (POMS)
Endpoint domain: Adverse events/effects
Primary endpoint: Pain at site of injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vibriocidal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Elasticity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean peak plasma concentration (Cmax) of Bendavia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Area Under the Curve (AUC) for Bendavia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Time post-dose of the peak plasma concentration (Tmax) of Bendavia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With On-Treatment Treatment-Emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Developing Anti-Drug Antibodies (ADAs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Developing Neutralizing Antibodies (NAbs)
Endpoint domain: Adverse events/effects
Primary endpoint: Children's anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean reaction time (RT) in ecological visual search task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Glycosylated A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GERD symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of patients changing pain status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Breathing Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Anti-varicella Zoster Virus (Anti-VZV) Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Agreement in tumor staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of therapeutic successes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of dentin bridge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appearance of dentin bridge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of Pulp Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Extension of Pulp Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gingival crevicular fluid levels of osteoprotegerin (OPG) and RANKL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes